Atopic Dermatitis Highlights From EADV 2022

Ana Maria Giménez-Arnau, MD, PhD


October 03, 2022

Significant therapeutic advances in atopic dermatitis (AD) were presented at the 2022 Congress of the European Academy of Dermatology and Venereology in Milan. Prof Ana Maria Giménez-Arnau from Universitat Pompeu Fabra in Barcelona selects several significant studies to review.

She begins by highlighting the PROLEAD prospective observational study from Germany, which examined efficacy of dupilumab in routine clinical use over 2 years. Giménez-Arnau concludes that there is still room for improvement in the treatment of patients with AD.

Continuing her focus on dupilumab, she cites a Liberty AD PRESCHOOL study showing that the drug is associated with improvement in quality of life among children aged 6 months to 5 years. Other Liberty AD PRESCHOOL studies at the conference spoke to safety and risk for infection with dupilumab in the same population.

Prof Giménez-Arnau next reports on lebrikizumab, a monoclonal antibody designed to bind with interleukin-13 that showed favorable results compared with placebo in two phase 3 studies: ADvocate 1 and 2.

She also discusses oral JAK inhibitors, baricitinib and upadacitinib, which were shown to be effective in treating AD in a Dutch BioDay Registry study.

Finally, she points to a 28-country study on patient-reported outcomes and disease severity measures with disease burden in AD, stressing the critical nature of patient input in management of AD.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.